Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
DGX enters its October 22 earnings report in an unusual position: short interest is jumping sharply while the stock drifts lower and options traders pile into puts at levels not far below the year's most defensive reading.
The most striking development this week is the pace of short rebuilding. Short interest climbed 22% in a single session on October 6, taking it to 3.25% of the free float, up 11% on the week. That follows a steady decline through September, when shorts were at roughly 3.9% of float in early September before covering through mid-month. The reversal is abrupt. What makes it less threatening than it might appear is the lending market: borrow availability is extremely loose at 767%, meaning there are nearly eight shares available to lend for every share already short. Borrowing costs remain cheap at 0.49%, down 16% over the past month. New shorts face no friction at all entering the position.
Options positioning reinforces the cautious tone. The put/call ratio has run above its 20-day average for the better part of two weeks, standing at 1.24 at Tuesday's close. That is not extreme in absolute terms but the sustained tilt above 1.0 is notable given it spent most of August and early September well below 1.0, with readings as low as 0.37 in early September. The shift reflects a clear rotation in how options traders are leaning. The 52-week high on the PCR is 1.38, so the current reading is elevated but not at its most defensive. The ORTEX short score has ticked up to 39.5, its highest level in the recent history shown, though still comfortably in the middle of the range.
The Street is not ringing alarm bells. Barclays lifted its target to $260 from $250 on October 7, keeping an Overweight rating, the most recent action. Several firms raised targets after the July results, including JP Morgan, Mizuho and Truist, though none moved off their existing rating. The consensus lands at a mean target of $248, not far above the $228.39 close, implying modest upside. The bull case centres on the consumer-initiated testing business, which delivered close to $250 million in revenue and grew 35%, and continued productivity gains. Bears point to the drag from lower volumes at Corewell and Fresenius, declining revenue per requisition, and an expectation of flat pricing in 2026. Valuation multiples have edged lower over the past 30 days: the trailing PE has slipped by about 0.9 turns to 19.3, and EV/EBITDA has fallen by roughly 0.2 turns to 12.1. The dividend factor score ranks in the 99th percentile, reflecting consistent income; other factor scores are squarely mid-table.
Insider activity over the past 90 days has been one-directional. The net position across open-market transactions is a disposal of 34,277 shares worth approximately $8.3 million. The CEO sold 10,000 shares at $242.72 on September 1, and the General Counsel executed a series of transactions on August 28 that left a combined net sale of over $5 million in open-market proceeds. Every recent trade flagged as an open-market sale was conducted under a pre-arranged 10b5-1 plan, so the sales reflect scheduled programs rather than discretionary conviction. No open-market purchases appear in the 90-day window. Among institutional holders, BlackRock added 134,000 shares and State Street added 136,000 shares in their most recent quarterly reports. T. Rowe Price has reduced its stake from 6.5% to 4.9% as last disclosed, a meaningful trim though the filing dates back to August.
Closest peer LH ended the week up about 0.9%, while WGS fell more than 5% and CSTL dropped nearly 9% on the week. DGX's 1.5% weekly decline puts it in the middle of a fragmented diagnostic peer group, neither leading the selloff nor offering shelter from it. Wikipedia attention for the company tracked at a z-score of 2.5 against its own prior 90 days as of late September, a notable spike in retail attention, though the dataset has no measured relationship to revenue and should be read as a gauge of public interest rather than anything more.
With the October 22 print 15 days away, the question is whether the short rebuild and options tilt reflect genuine concern about the revenue-per-requisition trend or simply pre-earnings hedging into a stock that has given back roughly 4% over the past month after a strong summer.
See the live data behind this article on ORTEX.
Open DGX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
